Akebia Therapeutics, Inc.
AKBA
$1.43
$0.075.15%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 118.62% | -95.96% | 126.80% | -13.80% | -133.50% |
| Total Depreciation and Amortization | 0.63% | 0.64% | -97.68% | 44.47% | -0.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.92% | 71.75% | 21.02% | -30.96% | 322.88% |
| Change in Net Operating Assets | 277.00% | 117.16% | -820.02% | 57.79% | 43.89% |
| Cash from Operations | 25.78% | 264.46% | -204.23% | 33.29% | 33.49% |
| Capital Expenditure | 38.89% | -600.00% | -800.00% | 0.00% | 93.10% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 38.89% | -181.82% | 7,800.00% | 0.00% | 93.10% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -- | 100.00% | -46,300.00% | -- | 100.00% |
| Issuance of Common Stock | -35.29% | -97.37% | 193.26% | 1,179.31% | 12,364.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | 100.00% | -- |
| Cash from Financing | -35.29% | -97.70% | 235.69% | 1,725.43% | -83.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.73% | -61.08% | 244.45% | 426.21% | -122.97% |